STOCK TITAN

Innate Pharma Sa SEC Filings

IPHA NASDAQ

Welcome to our dedicated page for Innate Pharma Sa SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Innate Pharma S.A.'s filings document the company's foreign private issuer reporting, oncology pipeline disclosures, governance matters, and share-capital information. Form 6-K reports furnish company press releases covering clinical-stage immunotherapy programs, business updates, investor and scientific conference activity, Annual General Meeting materials, and French share and voting-right notifications.

The company's Form 20-F annual report and Universal Registration Document address annual financial reporting, management discussion, corporate governance, statutory auditor reports, and risk factors for a biotechnology issuer developing antibody therapeutics. Filings also reference registration statements on Form F-3 and Form S-8 and disclose Nasdaq and Euronext Paris trading identifiers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
current report
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

How many Innate Pharma Sa (IPHA) SEC filings are available on StockTitan?

StockTitan tracks 36 SEC filings for Innate Pharma Sa (IPHA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Innate Pharma Sa (IPHA)?

The most recent SEC filing for Innate Pharma Sa (IPHA) was filed on September 15, 2025.